Daxor's Revenue Soars with 116.5% Annual Growth Daxor Corporation reported a remarkable 116.5% year-over-year revenue surge for Q4 2024. This growth, coupled with achieving cash flow breakeven in Q1 2025, underscores the company’s financial stability. Daxor is also advancing its next-generation blood volume analyzer, aiming for FDA approval, which could further expand its market reach.123